Intercellular adhesion molecule-1 gene polymorphisms in Behcet's Disease.

Authors: Boiardi, L  Salvarani, C  Casali, B  Olivieri, I  Ciancio, G  Cantini, F  Salvi, F  Malatesta, R  Govoni, M  Trotta, F  Filippini, D  Paolazzi, G  Nicoli, D  Farnetti, E  Macchioni, L 
Citation: Boiardi L, etal., J Rheumatol. 2001 Jun;28(6):1283-7.
Pubmed: (View Article at PubMed) PMID:11409120

OBJECTIVE: Intercellular adhesion molecule 1 (ICAM-1) is strongly expressed in vascular endothelial cells and perivascular inflammatory infiltrates in immunopathologic studies of Behcet's disease (BD) lesions. ICAM-1 genes may contribute to the inflammatory events responsible for the vessel damage in BD. We examined potential associations of ICAM-1 gene polymorphisms with BD susceptibility. METHODS: Case patients were 74 consecutive Italian patients with BD who were followed at the Bologna, Ferrara, Milano, Potenza, Prato, Reggio Emilia, and Trento rheumatology, ophthalmology, and neurology units over a 3 year period (1997-99) who satisfied the International Study Group criteria for BD; 228 healthy Italian blood donors from the same geographic areas were selected as control groups. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific oligonucleotide techniques for ICAM-1 polymorphisms at codon 241 (exon 4) and codon 469 (exon 6). RESULTS: The frequency of R241 was significantly higher in BD patients than in controls (20.3% vs 5.7%; p = 0.001, pcorr = 0.002, OR 4.2, 95% CI 1.9-9.3). The distribution of E/K 469 genotype was similar in patients and controls. Comparing patients with different clinical features, we found only a trend to higher frequency of R241 in patients with articular manifestations (21.4% vs 12.5%; p = 0.08). CONCLUSION: Our findings show that G/R 241 polymorphism of ICAM-1 is associated with BD susceptibility.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 8547575
Created: 2014-02-18
Species: All species
Last Modified: 2014-02-18
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.